PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Pliant Therapeutics, Inc. (PLRX) has received a Zacks Rank upgrade to 2 (Buy) due to an upward trend in earnings estimates, indicating potential for stock price increase [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Pliant Therapeutics suggest an improvement in the company's underlying business, likely leading to increased investor interest and stock price appreciation [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Pliant Therapeutics is expected to report earnings of -$2.72 per share, reflecting a 21.6% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Pliant Therapeutics has increased by 32.5%, indicating positive sentiment among analysts [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, highlighting their potential for market-beating returns [9][10]. - Pliant Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting favorable earnings estimate revisions and potential for stock price growth [10].